Subscribe
istock-510461153
fstop123 / iStockphoto.com
3 August 2017Americas

Boehringer has infringed 74 Humira patents, claims AbbVie

Boehringer Ingelheim has infringed 74 of AbbVie’s patents relating to arthritis medication Humira (adalimumab), AbbVie has alleged.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Judge orders Boehringer to disclose Humira biosimilar plans
28 February 2019   A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
Big Pharma
Boehringer hits China’s Qilu with cancer drug patent suit
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Judge orders Boehringer to disclose Humira biosimilar plans
28 February 2019   A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
Big Pharma
Boehringer hits China’s Qilu with cancer drug patent suit
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

More on this story

Big Pharma
Judge orders Boehringer to disclose Humira biosimilar plans
28 February 2019   A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
Big Pharma
Boehringer hits China’s Qilu with cancer drug patent suit
4 February 2021   Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent